Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
109 studies found for:    "Juvenile myelomonocytic leukemia"
Show Display Options
Rank Status Study
1 Recruiting Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)
Condition: Juvenile Myelomonocytic Leukemia
Interventions: Biological: Stem Cell Transplant;   Drug: Preparative Regimen
2 Active, not recruiting Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia
Condition: Juvenile Myelomonocytic Leukemia
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Other: Pharmacological Study;   Drug: Tacrolimus
3 Completed Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia
Condition: Juvenile Myelomonocytic Leukemia
Interventions: Drug: tipifarnib;   Drug: isotretinoin;   Drug: fludarabine phosphate;   Drug: cytarabine;   Radiation: radiation therapy;   Drug: cyclophosphamide;   Biological: anti-thymocyte globulin;   Procedure: allogeneic bone marrow transplantation;   Procedure: double-unit umbilical cord blood transplantation;   Procedure: umbilical cord blood transplantation;   Other: laboratory biomarker analysis
4 Terminated
Has Results
Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation
Condition: Leukemia
Interventions: Drug: cyclosporine;   Drug: cytarabine;   Drug: filgrastim;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: mitoxantrone hydrochloride;   Procedure: allogeneic bone marrow transplantation;   Procedure: umbilical cord blood transplantation;   Drug: Cis-Retinoic acid
5 Terminated
Has Results
Etanercept (Enbrel) for Juvenile Myelomonocytic Leukemia
Condition: Leukemia
Intervention: Drug: Etanercept
6 Active, not recruiting Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia
Conditions: Acute Myelogenous Leukemia;   Myelodysplastic Syndrome;   Juvenile Myelomonocytic Leukemia
Interventions: Drug: Fludarabine;   Drug: Busulfan;   Drug: Graft-versus-host disease (GVHD) Prophylaxis;   Drug: Gemtuzumab Ozogamicin;   Drug: Anti-Thymocyte Globulin;   Drug: Isotretinoin
7 Terminated Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML
Conditions: Acute Myeloid Leukemia;   Juvenile Myelomonocytic Leukemia;   Myelodysplastic Syndrome
Interventions: Drug: Gemtuzumab Ozogamicin;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Thymoglobulin;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Drug: Methotrexate
8 Recruiting Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)
Conditions: Myelodysplastic Syndrome;   Leukemia, Myelomonocytic, Juvenile
Intervention: Drug: Azacitidine
9 Recruiting Study for Epidemiology and Characterization of Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leucemia (JMML) in Childhood
Conditions: Myelodysplastic Syndromes;   Juvenile Myelomonocytic Leukemia
10 Recruiting Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation
Conditions: Acute Myelogenous Leukemia;   Acute Lymphoid Leukemia;   Juvenile Myelomonocytic Leukemia;   Myelodysplastic Syndrome
Interventions: Drug: azacitidine;   Biological: donor lymphocyte infusion
11 Not yet recruiting Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT)
Conditions: Acute Leukemias;   Chronic Leukemias;   Myelodysplastic Syndrome;   Juvenile Myelomonocytic Leukemia
Intervention: Drug: Busulfan/Cyclophosphamide
12 Active, not recruiting Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies
Conditions: Acute Lymphoblastic Leukaemias (ALL);   Acute Myeloid Leukaemias (AML);   Myelodysplastic Syndromes (MDS);   Juvenile Myelomonocytic Leukaemias (JMML)
Intervention: Drug: Treosulfan
13 Completed Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies
Conditions: Acute Lymphoblastic Leukemia;   Chronic Myelogenous Leukemia;   Juvenile Myelomonocytic Leukemia;   Myelodysplastic Syndrome;   Non-Hodgkin's Lymphoma
Interventions: Other: NK Cell Infusion;   Biological: Immunotherapy;   Device: Miltenyi Biotec CliniMACS device;   Drug: Interleukin-2 (IL-2);   Drug: Clofarabine;   Drug: Cyclophosphamide;   Drug: Etoposide
14 Recruiting Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies
Conditions: Acute Lymphoblastic Leukemia/Lymphoma;   Myelodysplasia;   Acute Myelogenous Leukemia;   Juvenile Myelomonocytic Leukemia;   Chronic Myelogenous Leukemia
15 Completed Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors
Conditions: Leukemia, Myeloid, Acute;   Leukemia, Lymphocytic, Acute, T-Cell;   Juvenile Myelomonocytic Leukemia Lymphoblastic;   T-cell Lymphoblastic Lymphoma;   Myelodysplastic Syndrome
Interventions: Procedure: Haploidentical donor derived natural killer cell infusion;   Drug: Chemotherapy;   Device: CliniMACS
16 Not yet recruiting Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)
Conditions: Chronic Myelomonocytic Leukemia;   Juvenile Myelomonocytic Leukemia;   Atypical Chronic Myeloid Leukemia;   Myeloproliferative Neoplasm;   Myelodysplastic Syndromes;   Myelofibrosis
Interventions: Drug: Pacritinib;   Drug: Decitabine
17 Unknown  Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias
Conditions: Myelodysplastic Syndrome;   Acute Myeloid Leukemia;   Myeloproliferative Disorders;   Acute Lymphocytic Leukemia;   Acute Promyelocytic Leukemia;   Acute Leukemia;   Chronic Myelogenous Leukemia;   Myelofibrosis;   Chronic Myelomonocytic Leukemia;   Juvenile Myelomonocytic Leukemia
Interventions: Drug: Clofarabine;   Drug: Cyclophosphamide
18 Recruiting CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
Conditions: Chronic Myeloid Leukemia (CML);   Acute Myelogenous Leukemia (AML);;   Myelodysplastic Syndrome (MDS);;   Juvenile Myelomonocytic Leukemia (JMML);;   Acute Lymphoblastic Leukemia (ALL);;   Lymphoma (Hodgkin's and Non-Hodgkin's)
Interventions: Device: CliniMACS CD34+ Reagent System;   Drug: Thiotepa;   Drug: Cyclophosphamide;   Drug: Alemtuzumab;   Drug: Tacrolimus;   Drug: Melphalan;   Drug: Busulfan;   Drug: Fludarabine;   Drug: Methylprednisolone
19 Terminated
Has Results
T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant
Conditions: Acute Lymphoblastic Leukemia;   Acute Myelocytic Leukemia;   Chronic Myelocytic Leukemia;   Juvenile Myelomonocytic Leukemia;   Myelodysplastic Syndrome;   Hodgkin or Non-Hodgkin Lymphoma;   Sarcoma, Myeloid
Interventions: Drug: clofarabine;   Drug: cytarabine;   Drug: busulfan;   Drug: Plerixafor;   Drug: cyclophosphamide;   Drug: antithymocyte globulin (rabbit);   Biological: stem cells;   Drug: Tacrolimus;   Drug: mycophenolate mofetil
20 Completed Stem Cell Transplantation for Patients With Hematologic Malignancies
Conditions: Acute Lymphoblastic Leukemias;   Acute Myelocytic Leukemia;   Chronic Myeloid Leukemia;   Juvenile Myelomonocytic Leukemia;   Myelodysplastic Syndrome;   Hemoglobinuria, Paroxysmal;   Non-Hodgkin Lymphoma
Interventions: Procedure: Allogeneic Stem Cell Transplantation;   Drug: Chemotherapy and antibodies

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.